The early-onset pancreatic cancer paradox: a systematic review and meta-analysis

Clicks: 4
ID: 331905
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #370 of 374 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 374 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Globally, the rate of early-onset pancreatic cancer (EOPC) is increasing, but its clinical features and outcomes relative to average-onset pancreatic cancer (AOPC) remain uncertain. We compared clinicopathological features, treatment patterns, and survival outcomes. METHODS: PubMed, Embase, Web of Science, the Cochrane Library, and Scopus were searched through January 2026 (PROSPERO: CRD420261346604). Observational studies comparing EOPC with AOPC using age-based thresholds were included. Study quality was assessed with the Newcastle-Ottawa Scale and ROBINS-E. Hazard and odds ratios were pooled using random-effects models for 39 outcomes across 9 predefined PROSPERO domains. All tests were two-sided. Certainty was assessed using GRADE. RESULTS: Forty-eight studies from 15 countries were included, encompassing 1,659,432 patients (non-overlapping estimate: 695,936). EOPC patients had a lower prevalence of diabetes (odds ratio [OR], 0.39; 95% confidence interval [CI], 0.21 to 0.72), more advanced disease (stage IV: OR, 1.18; 95% CI, 1.02 to 1.36), and higher chemotherapy utilization (OR, 2.04; 95% CI, 1.69 to 2.45; P < .001). Overall survival was comparable (hazard ratio, 1.03; 95% CI, 0.86 to 1.23; P = .76; prediction interval, 0.50 to 2.12). Exploratory dose-response meta-regression suggested a nonlinear (U-shaped) association between age threshold and survival (P = .008). GRADE certainty was very low for all outcomes. CONCLUSIONS: Patients with EOPC present with more advanced disease, receive more aggressive treatment, and achieve comparable survival, although certainty is very low. These findings support equitable access to intensive multimodal therapy and germline testing before age 50; however, stage-specific survival data are required to confirm these observations.
Reference Key
openalex_W7221070664 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Rexiati Ruze, Musitapa Zayier, Aboduhaiwaier Aboduhelili, Talaiti Tuergan, Aboduaini Abulizi, Qiang Guo, Ruiqing Zhang, Paizula Shalayiadang, Ahan Ayifuhan, Tiemin Jiang, Yingmei Shao, Tuerganaili Aji
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag373
URL
https://doi.org/10.1093/jnci/djag373
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.